CytomX Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
CytomX Therapeutics, Inc. (CTMX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.41 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-16
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.41, a 16.53% increase from fiscal 2024.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.21.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $1.77, a 55.42% decline from fiscal 2021.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $3.97, a 0.76% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.41 10-K · filed 2026-03-16 | |
| 2024-12-31 | $1.21 10-K · filed 2026-03-16 | |
| 2022-12-31 | $1.77 10-K · filed 2023-03-27 | |
| 2021-12-31 | $3.97 10-K/A · filed 2023-03-27 | |
| 2020-12-31 | $3.94 10-K/A · filed 2023-03-27 | |
| 2019-12-31 | $7.03 10-K/A · filed 2023-03-27 | |
| 2018-12-31 | $14.21 10-K · filed 2021-02-24 | $14.21 10-K · filed 2019-02-27 |
| 2017-12-31 | $8.21 10-K · filed 2020-02-27 | $8.21 10-K · filed 2018-03-07 |
| 2016-12-31 | $8.94 10-K · filed 2019-02-27 | |
| 2015-12-31 | $7.17 10-K · filed 2018-03-07 | |
| 2014-12-31 | $0.94 10-K · filed 2017-03-02 | |
| 2013-12-31 | $0.50 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |